Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) and Sera Prognostics (NASDAQ:SERA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Bicycle Therapeutics and Sera Prognostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bicycle Therapeutics | 2 | 3 | 5 | 0 | 2.30 |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
Bicycle Therapeutics currently has a consensus price target of $13.57, indicating a potential upside of 281.33%. Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 156.41%. Given Bicycle Therapeutics’ higher possible upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than Sera Prognostics.
Volatility & Risk
Bicycle Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
Profitability
This table compares Bicycle Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bicycle Therapeutics | -169.75% | -26.02% | -22.30% |
| Sera Prognostics | -34,866.67% | -49.61% | -35.58% |
Insider and Institutional Ownership
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Bicycle Therapeutics and Sera Prognostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bicycle Therapeutics | $72.86 million | 3.42 | -$218.96 million | ($2.03) | -1.75 |
| Sera Prognostics | $96,000.00 | 881.44 | -$31.93 million | ($0.67) | -3.20 |
Sera Prognostics has lower revenue, but higher earnings than Bicycle Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Bicycle Therapeutics beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
